Amgen’s chief financial officer Jonathan Peacock has left his role as chief financial officer at the company.
He is replaced by Amgen veteran Michael Kelly, who takes on the role temporarily while the search for a successor is undertaken. Amgen said Peacock will remain employed with the company until May to assist with the transition.
Amgen was vague on the reasons for Peacock’s departure, saying it was down to his desire to “pursue broader career opportunities”.
The company’s CEO Robert Bradway added: “Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company’s strategy for growth and in delivering value for shareholders.”
Acting chief financial officer Kelly has been with Amgen since 2003 serving in several senior finance roles, including most recently as chief financial officer for international commercial operations.
His prior experience includes roles at Tanox, Biogen and Monsanto Life Sciences.
“Michael Kelly is an experienced financial executive,” said Bradway. “I am delighted to have him reporting to me as acting chief financial officer while we search for Jon’s successor.”